Population pharmacokinetics of trabectedin in adolescent patients with cancer.

Abstract

To characterize the trabectedin population pharmacokinetics in children and adolescent patients with cancer and compare it with the trabectedin pharmacokinetics in adults. Plasma concentrations from ten adolescent and three children with cancer (age range 4.0-17.0years) treated with trabectedin at doses ranging from 1.1 to 1.7mg/m2, administered as a 24-h continuous intravenous infusion every 3weeks, were available for the analysis. An external model evaluation was performed to verify whether a previously developed adult population pharmacokinetic model was predictive of the pediatric plasma concentrations of trabectedin. The maximum a posteriori estimation of the individual pharmacokinetic parameters for pediatric patients was conducted, after successful completion of the external evaluation step. The relationships between pharmacokinetic parameters and body size were evaluated. External evaluation methods showed no major differences between the adult population and children and adolescent patients of this study. The mean ± standard deviation (SD) of the individual estimated clearance and central volume of distribution in these children/adolescent patients was 36.4 ± 16.1L/h and 13.2 ± 6.54L, respectively. These values were similar to the typical values reported for adult patients-37.6L/h and 13.9L (for females) and 16.1L (for males). The median area under the plasma concentration versus time curve (AUC) in children/adolescent patients was 55.1µgh/L, while in the adult population the median AUC was 61.3µgh/L, both administered a 1.5mg/m2 dose regimen with mean (range) BSA for adults = 1.86 (0.90-2.80) vs children/adolescent patients = 1.49 (0.66-2.54). The adult population pharmacokinetic model adequately described the trabectedin plasma concentrations and its variability in the pediatric population of patients involved in this assessment that mostly comprised adolescents. The trabectedin systemic exposure achieved in this population was comparable (within 12%) to the exposure obtained in adult population when the same dose, expressed in mg/m2, was administered.